Fibrodysplasia ossificans progressiva-When bone suddenly forms within muscle

被引:0
|
作者
Grossmann, Nadine Z. [1 ,2 ]
Hildebrandt, Susanne [1 ,2 ]
Morhart, Rolf [3 ]
Kallinich, Tilmann [4 ]
Semler, Oliver [5 ,6 ]
Knaus, Petra [1 ,2 ,7 ]
机构
[1] Free Univ Berlin, Inst Chem Biochem, Berlin, Germany
[2] Univ Med Berlin, Berlin Brandenburg Sch Regenerat Therapies, Charite, Berlin, Germany
[3] Klinikum Garm Partenkirchen, Kinder & Jugendmedizin, Garmisch Partenkirchen, Germany
[4] Univ Med Berlin, Padiatr Rheumatol, Charite, Berlin, Germany
[5] Univ Cologne, Med Fak, Cologne, Germany
[6] Uniklin Koln, Klinik Poliklin Kinder & Jugendmed, Cologne, Germany
[7] Free Univ Berlin, Inst Chem & Biochem, Thielallee 63, D-14195 Berlin, Germany
关键词
Fibrodysplasia ossificans progressiva; Heterotopic ossification; Myositis ossificans; Soft tissue swelling; Congenital hallux valgus; FOP;
D O I
10.1007/s00112-023-01816-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic condition caused by a point mutation in the ACVR1 gene. There are two clinical features indicative of FOP: 1) a congenital malformation of the great toe(s), similar to a hallux valgus and 2) unexplained soft tissue swelling usually resulting in heterotopic ossifications (HO). Early recognition of these two features is very important to avoid misdiagnosis and incorrect treatment and to ensure the correct diagnosis as early as possible by genetic testing of the ACVR1 gene. As soon as this diagnosis is available it is advisable for the affected person to see a FOP specialist and to establish contact with the German patient organization "FOP e. V.".All invasive interventions should be strictly avoided, as they can trigger irreversible HO. The complexity and systemic course of FOP requires the establishment and collaboration of an interdisciplinary team for optimal care of affected individuals. Treatment of FOP flare-ups and subsequent ossification is currently symptomatic according to the international guidelines of the ICC on FOP (www.iccfop.org). Targeted treatment approaches in current clinical trials aim to influence the bone morphogenetic protein (BMP) signalling pathway at multiple levels to halt or slow disease progression.While more than 95% of all affected individuals have the classical point mutation, a small number of affected individuals have variant mutations. Each of these mutations leads to hypersensitivity and overactivation of the ACVR1 receptor and results in an increased BMP signalling response.
引用
收藏
页数:8
相关论文
共 30 条
  • [21] [18F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders
    Zwama, Jolien
    Rosenberg, Neeltje M.
    Verheij, Vincent A.
    Raijmakers, Pieter G. H. M.
    Yaqub, Maqsood
    Botman, Esmee
    de Ruiter, Ruben D.
    Garrelfs, Mark R.
    Bokenkamp, Arend
    Micha, Dimitra
    Schwarte, Lothar A.
    Teunissen, Bernd P.
    Lammertsma, Adriaan A.
    Boellaard, Ronald
    Eekhoff, Elisabeth M. W.
    BIOMOLECULES, 2024, 14 (10)
  • [22] Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography
    Farid, Alexander
    Golden, Emma
    Robicheau, Sara
    Hu, Alice
    Cheung, Kin
    Yu, Paul B.
    Rutkove, Seward B.
    Upadhyay, Jaymin
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [23] Comparison of PET/CT versus CT only in the assessment of new heterotopic ossification bone lesions in patients with fibrodysplasia ossificans progressiva
    Trotter, Dinko Gonzalez
    Mcginniss, Jennifer
    Mohammadi, Kusha
    Musser, Bret J.
    Herman, Gary A.
    Mellis, Scott
    Economides, Aris N.
    BONE, 2025, 190
  • [24] The serum levels of activin A and bone morphogenetic protein-4 and-6 in patients with fibrodysplasia ossificans progressiva
    Ye, Zhengqin
    Wang, Siyi
    Shan, Chang
    Zhu, Qi
    Xue, Ying
    Zhang, Keqin
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [25] Fibrodysplasia Ossificans Progressiva - A Rare Genetic Disorder and the Role of Technetium-99m Methylene Diphosphonate Bone Scan
    Gupta, Nitin
    Pruthi, Ankur
    Kumar, Suneel
    Verma, Ritu
    Belho, Ethel Shangne
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2019, 34 (03): : 209 - 212
  • [26] The neuron-specific enolase-bone morphogenic protein 4 transgenic mouse: A fibrodysplasia ossificans progressiva-like animal model
    Kan L.
    Clinical Reviews in Bone and Mineral Metabolism, 2005, 3 (3-4): : 235 - 237
  • [27] Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva
    Fukuda, Toru
    Kohda, Masakazu
    Kanomata, Kazuhiro
    Nojima, Junya
    Nakamura, Atsushi
    Kamizono, Jyunji
    Noguchi, Yasuo
    Iwakiri, Kiyofumi
    Kondo, Takeo
    Kurose, Junichi
    Endo, Ken-ichi
    Awakura, Takeshi
    Fukushi, Junichi
    Nakashima, Yasuharu
    Chiyonobu, Tomohiro
    Kawara, Akira
    Nishida, Yoshihiro
    Wada, Ikuo
    Akita, Masumi
    Komori, Tetsuo
    Nakayama, Konosuke
    Nanba, Akira
    Maruki, Yuichi
    Yoda, Tetsuya
    Tomoda, Hiroshi
    Yu, Paul B.
    Shore, Eileen M.
    Kaplan, Frederick S.
    Miyazono, Kohei
    Matsuoka, Masaru
    Ikebuchi, Kenji
    Ohtake, Akira
    Oda, Hiromi
    Jimi, Eijiro
    Owan, Ichiro
    Okazaki, Yasushi
    Katagiri, Takenobu
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (11) : 7149 - 7156
  • [28] Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification?
    Hegyi, L
    Gannon, FH
    Glaser, DL
    Shore, EM
    Kaplan, FS
    Shanahan, CM
    JOURNAL OF PATHOLOGY, 2003, 201 (01) : 141 - 148
  • [29] Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1R206H-Specific Human Cellular and Zebrafish Models
    Wentworth, Kelly L.
    Lalonde, Robert L.
    Groppe, Jay C.
    Brewer, Niambi
    Moody, Tania
    Hansberry, Steven
    Taylor, Kimberly E.
    Shore, Eileen M.
    Kaplan, Frederick S.
    Pignolo, Robert J.
    Yelick, Pamela C.
    Hsiao, Edward C.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (11) : 2058 - 2076
  • [30] ALK2 R206H Mutation Linked to Fibrodysplasia Ossificans Progressiva Confers Constitutive Activity to the BMP Type I Receptor and Sensitizes Mesenchymal Cells to BMP-Induced Osteoblast Differentiation and Bone Formation
    van Dinther, Maarten
    Visser, Nils
    de Gorter, David J. J.
    Doorn, Joyce
    Goumans, Marie-Jose
    de Boer, Jan
    ten Dijke, Peter
    JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (06) : 1208 - 1215